Completed

A New Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Data Collection

Who is being recruted

Anemia
+11

+ Anemia, Hemolytic
+ Anemia, Hemolytic, Congenital
From 18 to 60 Years
See all eligibility criteria
How is the trial designed

Prevention Study

Interventional
Study Start: December 2003
See protocol details

Summary

Principal SponsorWalter Reed Army Institute of Research (WRAIR)
Last updated: January 14, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: December 1, 2003Actual date on which the first participant was enrolled.

This study will evaluate a new and safe testing method for identifying medicines that can cause problems in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. We are looking for volunteers with G6PD deficiency who would be willing to donate blood samples.

Official TitleA New Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency 
NCT00076323
Principal SponsorWalter Reed Army Institute of Research (WRAIR)
Last updated: January 14, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details
14 patients to be enrolledTotal number of participants that the clinical trial aims to recruit.
Prevention Study
Prevention studies aim to stop a disease from developing. They often involve people at risk and test things like vaccines, lifestyle changes, or preventive medications.

How participants are assigned to different groups/arms
In this clinical study, participants are assigned to groups based on specific criteria, such as their medical history or a doctor's recommendation. This approach ensures that treatments are given to those who may benefit the most, based on known factors.

Other Ways to Assign Participants
Randomized allocation: Participants are assigned randomly, like flipping a coin, to ensure fairness and reduce bias.
None (Single-arm trial): If the study has only one group, all participants receive the same treatment, and no allocation is needed.

How treatments are given to participants
In this study, all participants receive the same treatment. This approach is often used to evaluate the effects of a single intervention without comparing it to another.

Other Ways to Assign Treatments
Parallel assignment: Participants are split into separate groups, each receiving a different treatment.
Cross-over assignment: Participants switch between treatments during the study.
Factorial assignment: Participants receive different combinations of treatments.
Sequential assignment: Participants receive treatments one after another in a specific order, possibly based on individual responses.
Other assignment: Treatment assignment does not follow a standard or predefined design.

How the interventions assigned to participants is kept confidential
Everyone involved in the study knows which treatment is being given. This is typically used when it's not possible or necessary to hide the treatment details from participants or researchers.

Other Ways to Mask Information
Single-blind: Participants do not know which treatment they are receiving, but researchers do.
Double-blind: Neither participants nor researchers know which treatment is given.
Triple-blind: Participants, researchers, and outcome assessors do not know which treatment is given.
Quadruple-blind: Participants, researchers, outcome assessors, and care providers all do not know which treatment is given.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria
Any sexBiological sex of participants that are eligible to enroll.
From 18 to 60 YearsRange of ages for which participants are eligible to join.
Healthy volunteers allowedIf individuals who are healthy and do not have the condition being studied can participate.
Conditions
Pathology
Anemia
Anemia, Hemolytic
Anemia, Hemolytic, Congenital
Carbohydrate Metabolism, Inborn Errors
Favism
Foodborne Diseases
Glucosephosphate Dehydrogenase Deficiency
Hematologic Diseases
Metabolic Diseases
Metabolism, Inborn Errors
Plant Poisoning
Poisoning
Genetic Diseases, Inborn
Chemically-Induced Disorders
Criteria

Inclusion: * Normal clinical evaluation * Willing and able to make all scheduled visits Exclusion: * pregnant or planning pregnancy * Have taken any anti-malarial medication in past month * Positive blood tests for HIV and specific types of hepatitis * Allergic to primaquine

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Study Objectives
Study Objectives
Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has 1 location
Suspended
Walter Reed Army Institute of ResearchSilver Spring, United StatesSee the location
CompletedOne Study Center